Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer in the United States

IMPORTANCE: Immune checkpoint inhibitor combination therapy has recently become the standard of care for first-line treatment of metastatic nonsquamous non–small cell lung cancer. The implications of these first-line treatments are considerable, given the potential population of patients eligible to...

Descripción completa

Detalles Bibliográficos
Autores principales: Criss, Steven D., Mooradian, Meghan J., Watson, Tina R., Gainor, Justin F., Reynolds, Kerry L., Kong, Chung Yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764123/
https://www.ncbi.nlm.nih.gov/pubmed/31553470
http://dx.doi.org/10.1001/jamanetworkopen.2019.11952

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764123/
https://www.ncbi.nlm.nih.gov/pubmed/31553470
http://dx.doi.org/10.1001/jamanetworkopen.2019.11952

Ejemplares similares